+A -A

Comparative View:

2Q16 Create chart
Net sales revenues 1,012,606
Change in Fair Value of Biological Assets 40,427
Cost of Goods Sold -653,957
Depreciation / Amortization / exhaustion -101,631
Exhaustion of biological assets -23,022
Gross Profit 274,423
Selling Expenses -152,714
General and Administrative Expenses -34,854
Management Compensation -3,564
Other Operating Compensation -7,223
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 76,068
Financial Income 42,959
Financial Expenses -122,124
Income Before Income Tax and Social Contribution -3,097
Income and social contribution taxes - current -38,284
Income Tax and Social Contribution - Deferred 42,104
Effect profit from discontinued operation null
Net Income 723
Recurring Net Income 723
Recurring EBITDA 171,657
EBITDA Margin 17.0 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza